Vita 34 logo

Vita 34

Stock
Stock
ISIN: DE000A0BL849
Ticker: V3V
DE000A0BL849
V3V

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

 


$0.179

CHART BY

Frequently asked questions

The market capitalization of Vita 34 is $59.11M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Vita 34's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.511. EPS indicates the company's profitability on a per-share basis.
Currently, 1 analysts cover Vita 34's stock, with a consensus target price of $7.549. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Vita 34 reported a revenue of $101.95M.
Vita 34's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $5.97M. EBITDA measures the company's overall financial performance.
Vita 34 has a free cash flow of $5.31M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Vita 34 employs approximately 742 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
The free float of Vita 34 is 5.50M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$59.11M
EPS (TTM) 
-$0.511
Free Float 
5.50M
Revenue (TTM) 
$101.95M
EBITDA (TTM) 
$5.97M
Free Cashflow (TTM) 
$5.31M

Pricing

1D span
$3.349$3.451
52W span
$2.946$8.403

Analyst Ratings

The price target is $7.549 and the stock is covered by 1 analysts.

Buy

1

Hold

0

Sell

0

Information

FamiCord AG engages in the collection, logistics, processing, and storage of stem cells from umbilical cord blood, umbilical cord tissue, and other postnatal tissues, serving as a full-service provider for cryopreservation. It also engages in the development of products and drugs derived from cells, tissues, and blood for medical applications. Additionally, FamiCord is active in Cell & Gene therapies and operates as a CDMO. The company was founded by Eberhard F. Lampeter on April 28, 1997 and is headquartered in Leipzig, Germany.

Employees
742
Industries
Biotechnology
Sector
Health Care

Identifier

ISIN
DE000A0BL849
Primary Ticker
V3V

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation